SCHEDULE 13G: CVI Investments and Heights Capital Management Disclose 5.8% Stake in Helius Medical Technologies

CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc., have jointly disclosed a beneficial ownership of 5.8% in Helius Medical Technologies, Inc., totaling 183,450 shares of Class A Common Stock.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. (collectively, "Reporting Persons") have filed a Schedule 13G indicating beneficial ownership of Helius Medical Technologies, Inc.
• The Reporting Persons collectively own 183,450 shares of Helius Medical Technologies, Inc.'s Class A Common Stock.
• This ownership represents 5.8% of the total Class A Common Stock outstanding.
• Heights Capital Management, Inc. acts as the investment manager for CVI Investments, Inc. and exercises shared voting and dispositive power over these shares.
• The filing certifies that the shares were not acquired for the purpose of changing or influencing the control of Helius Medical Technologies, Inc.
• The total outstanding shares of Class A Common Stock for Helius Medical Technologies, Inc. were 3,155,111 as of the completion of an offering referenced in a Prospectus filed on June 6, 2025.

Sentiment

Score: 6

Explanation: The document is a factual regulatory filing disclosing beneficial ownership. The acquisition of a 5.8% stake by institutional investors can be viewed as a moderately positive signal of confidence in the company, but the filing itself is neutral in tone and content.

Positives

• Increased institutional ownership by CVI Investments, Inc. and Heights Capital Management, Inc. may signal confidence in Helius Medical Technologies, Inc.

Negatives

• No explicit negatives are mentioned in this regulatory filing.

Risks

• No specific risks related to Helius Medical Technologies, Inc. are detailed in this ownership disclosure.

Future Outlook

The document does not provide specific forward-looking statements or guidance regarding Helius Medical Technologies, Inc.'s future performance or strategic direction. It is solely an ownership disclosure.

Management Comments

• The filing includes a certification from the reporting persons stating that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing indicates a significant institutional investment in Helius Medical Technologies, Inc., a company operating in the medical technology sector. Such disclosures are common for investment firms crossing a 5% ownership threshold, reflecting their investment strategies within the healthcare or med-tech industry.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure for institutional investors acquiring more than 5% of a company's voting class of securities.
• It does not contain performance metrics or operational results that would allow for a direct comparison to industry-specific benchmarks or competitor performance.
• The ownership stake itself is a factual disclosure rather than a performance indicator.

Related Party Transactions

• The Limited Power of Attorney granted by CVI Investments, Inc. to Heights Capital Management, Inc. on July 16, 2015, establishes a formal agency relationship for investment management purposes.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may influence investor perception and potentially stock liquidity.
• Management: Awareness of a substantial institutional holder may influence strategic decisions, though the filing explicitly states the stake is not for control purposes.

Next Steps

• The document does not specify any future actions, events, or milestones for Helius Medical Technologies, Inc. or the reporting persons beyond the ongoing investment management relationship.

Key Dates

Keywords

Helius Medical Technologies, CVI Investments, Heights Capital Management, Schedule 13G, Beneficial Ownership, Class A Common Stock, Institutional Ownership, Investment Management, SEC Filing, Medical Technology